BHUBANESWAR: The New Year seems to have ushered in a major breakthrough for thalassaemia patients with the US Food and Drug ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

Agios Pharmaceuticals AGIO announced that the FDA has approved Aqvesme (mitapivat) for the treatment of adult patients with ...

Google’s last couple of QPR updates for Android 16 have been nothing short of incredible. QPR1 brought Google’s excellent Material 3 Design UI to Pixel phones, while this month’s QPR2 update added new ...

Today’s first public beta of iOS 26.3 is likely the last beta we’ll get from Apple before the company takes a holiday break. Understandably then, the release is light on new features and changes. A ...

Apple has officially released the first beta of iOS 26.3, providing users and developers with an early look at the latest features, performance upgrades, and regulatory compliance updates. This beta ...